Health Matters
Printing is not available for Health Matters content.
Subscribers can read every article in full at health-matters.io.

25.08.2026

GLP-1 Generics Could Reshape Local Obesity Market

GLP-1 generics could cut obesity drug costs, challenge illegal sales and expand access as more semaglutide products seek approval.

This article is for Health Matters subscribers

Subscribers read every article in full, receive the daily briefing and have access to the complete archive.

Subscribe Log in

Aspen Pharma, generic medicines, GLP-1, obesity, ozempic, Pharmaceutical Industry, public healthcare, Ranbaxy, SAHPRA, semaglutide, Sun Pharma

More from Health Matters

23.10.2026

ARV Tender Suffers a Blow as High Court Sets Aside Contracts

The High Court set aside R12.6bn in TLD contracts in the ARV tender, ordering Cipla’s inclusion and excluding Viatris and Innovata.

23.10.2026

Financial Stress Is the Leading Driver of Poor Mental Health

23.10.2026

Opioid Overprescribing Raises Safety Concerns

Experts warn that opioid overprescribing after minor surgery risks addiction and waste, and paracetamol and NSAIDs often suffice.